Full Press Release Details
Contact: Investor Contact:
Dr. Bernard Kasten Dianne Will
SIGA Technologies, Inc. Willstar Consultants, Inc.
Chief Executive Officer (518) 398-6222
(212) 672-9100 dwill@willstar.net
SIGA TECHNOLOGIES TO PRESENT AT THE RODMAN & RENSHAW TECHVEST 6TH ANNUAL
HEALTHCARE CONFERENCE ON OCOTBER 27th
New York, NY - October 25, 2004 - SIGA Technologies, Inc. (NASDAQ: SIGA)
announced today that Dr. Dennis Hruby, SIGA's Chief Scientific Officer, will
present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference on
Wednesday, October 27th at 10:50am EST. A live webcast of this presentation will
be available at: http://www.wallstreetwebcasting.com/webcast/rrshq4/siga/ or via
the Company's website at www.siga.com. An archived presentation will be
available for 90 days.
"We look forward to increasing the awareness about our development programs in
the areas of vaccines and anti-infectives to prevent or treat diseases caused by
Category A Pathogens as defined by the Centers for Disease Control and
Prevention (CDC), said Dr. Hruby. "During the presentation we will give an
update on our pre-clinical research in smallpox and viral hemorrhagic fevers."
SIGA recently announced that the company's lead smallpox compound, SIGA-246,
has demonstrated significant antiviral activity against several mouse models
of poxvirus disease. In one of these studies, oral administration of
SIGA-246 protected mice from lethal doses of ectromelia virus. Ectromelia
virus is closely related to human smallpox virus and causes a similar type of
disease in mice (i.e. mousepox). SIGA-246 also was found to reduce disease
spread and lesion formation in treated mice with no obvious toxicity.
The Rodman & Renshaw Techvest 6th Annual Healthcare Conference will be held at
The Waldorf Astoria Hotel in New York City. Analysts and portfolio managers are
invited to attend this presentation by contacting Rodman & Renshaw Conference
Information at (212) 356-0529 to register or register on-line at
ConferenceMain&bgcolor=wht.
About SIGA Technologies, Inc.
SIGA Technologies is applying bacterial genomics in the design and development
of novel products for the prevention and treatment of serious infectious
diseases, with an emphasis on products for biological warfare defense. SIGA has
the potential of becoming a significant force in the discovery of vaccine and
pharmaceutical agents to fight emerging pathogens. SIGA's product development
programs emphasize the increasingly serious problem of drug resistant bacteria
and emerging pathogens. SIGA's vaccine and drug platforms are based on its
pioneering research into the structure, function and processing of bacterial
surface proteins. SIGA is leveraging these platforms through multiple strategic
partners, including the National Institutes of Health and TransTech Pharma, Inc.
For more information about SIGA, please visit SIGA's Web site at www.siga.com.
This news release contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements, including statements regarding the efficacy and intended utilization
of SIGA's technologies under development, are not guarantees of future
performance. Actual results may differ materially from the expectations
contained in the forward-looking statements. Factors that may cause such
differences include the risk that potential products that appeared promising in
early research or clinical trials to SIGA or its collaborators do not
demonstrate efficacy or safety in subsequent pre-clinical or clinical trials,
and the risk that SIGA or its collaborators will not obtain appropriate or
necessary governmental approvals to market products tested in such trials. More
detailed information about SIGA and the factors discussed above is set forth in
SIGA's filings with the Securities and Exchange Commission, including SIGA's
Annual Report on Form 10-K for the fiscal year ended December 31, 2003, and in
other documents that SIGA has filed with the U.S. Securities and Exchange
Commission. Investors and security holders are urged to read those documents
free of charge at the Commission's web site at www.sec.com. Those documents may
also be obtained free of charge from SIGA. SIGA does not undertake to publicly
update or revise its forward-looking statements as a result of new information,
future events or otherwise.